UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ki67 in breast cancer: prognostic and predictive potential

The lancet oncology, 2010-02, Vol.11 (2), p.174-183

2010

Volltextzugriff (PDF)

The HER‐2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER‐2 Therapy and Personalized Medicine

The oncologist (Dayton, Ohio), 2009-04, Vol.14 (4), p.320-368

2009

Volltextzugriff (PDF)

The Decrease in Breast-Cancer Incidence in 2003 in the United States

The New England journal of medicine, 2007-04, Vol.356 (16), p.1670-1674

2007

Volltextzugriff (PDF)

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5700-5706

2009

Volltextzugriff (PDF)

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

Journal of clinical oncology, 2008-09, Vol.26 (25), p.4063-4071

2008

Volltextzugriff (PDF)

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2716-2725

2005

Volltextzugriff (PDF)

Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer

Journal of clinical oncology, 2001-02, Vol.19 (4), p.980-991

2001

Volltextzugriff (PDF)

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study

The lancet oncology, 2009-11, Vol.10 (11), p.1070-1076

2009

Volltextzugriff (PDF)

Prediction Model for Estimating the Survival Benefit of Adjuvant Radiotherapy for Gallbladder Cancer

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2112-2117

2008

Volltextzugriff (PDF)

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

The New England journal of medicine, 2019-06, Vol.380 (25), p.2395-2405

2019

Volltextzugriff (PDF)

Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102

Journal of clinical oncology, 2005-11, Vol.23 (33), p.8313-8321

2005

Volltextzugriff (PDF)

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

Clinical cancer research, 2010-12, Vol.16 (24), p.6169-6176

2010

Volltextzugriff (PDF)

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

JAMA : the journal of the American Medical Association, 2010-10, Vol.304 (15), p.1684

2010

Volltextzugriff (PDF)

Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial

Clinical cancer research, 2009-08, Vol.15 (16), p.5258-5266

2009

Volltextzugriff (PDF)

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

The New England journal of medicine, 2009-02, Vol.360 (6), p.573-587

2009

Volltextzugriff (PDF)

Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2282-2290

2011

Volltextzugriff (PDF)

The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention

Cancer prevention research (Philadelphia, Pa.), 2010-06, Vol.3 (6), p.686-688

Ravdin, Peter M

2010

Volltextzugriff (PDF)

Myeloperoxidase Genotypes and Enhanced Efficacy of Chemotherapy for Early-Stage Breast Cancer in SWOG-8897

Journal of clinical oncology, 2009-10, Vol.27 (30), p.4973-4979

2009

Volltextzugriff (PDF)

Independent Prognostic Value of Screen Detection in Invasive Breast Cancer

JNCI : Journal of the National Cancer Institute, 2011-04, Vol.103 (7), p.585-597

2011

Volltextzugriff (PDF)

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

Breast cancer research and treatment, 1998-01, Vol.52 (1-3), p.227-237

1998

Volltextzugriff (PDF)

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

JAMA oncology, 2020-04, Vol.6 (4), p.505

2020

Volltextzugriff (PDF)

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

European journal of cancer (1990), 2011-12, Vol.47 (18), p.2742-2749

2011

Volltextzugriff (PDF)

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years

European journal of cancer (1990), 2017-06, Vol.78, p.37-44

2017

Volltextzugriff (PDF)

Epidemiology of GIST in the Era of Histology Codes--Letter

Cancer epidemiology, biomarkers & prevention, 2015-06, Vol.24 (6), p.998-998

2015

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(110)
Tagungsberichte
(1)

Sprache

Englisch
(111)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ki67 in breast cancer: prognostic and predictive potential

The HER‐2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER‐2 Therapy and Personalized Medicine

The Decrease in Breast-Cancer Incidence in 2003 in the United States

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study

Prediction Model for Estimating the Survival Benefit of Adjuvant Radiotherapy for Gallbladder Cancer

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues

The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention

Myeloperoxidase Genotypes and Enhanced Efficacy of Chemotherapy for Early-Stage Breast Cancer in SWOG-8897

Independent Prognostic Value of Screen Detection in Invasive Breast Cancer

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years

Epidemiology of GIST in the Era of Histology Codes--Letter

Suchergebnisse filtern